Jessica Hergert

January 05, 2022

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

November 14, 2021

Nuanced and multidisciplinary decision making are needed to optimize and personalize locoregional, systemic, and supportive care in metastatic breast cancer.

November 12, 2021

The COVID-19 pandemic has demonstrated that personalized medicine should consider social determinants of health disparities as well as genomic factors.

November 04, 2021

The increased risk of prostate cancer associated with MSH2 and MSH6 pathogenic variants point to a need for annual PSA screening in men over the age of 40.

November 03, 2021

CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.

October 30, 2021

Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.

October 28, 2021

Antoinette Wozniak, MD, FACP, FASCO, outlines the importance of careful patient monitoring in lung cancer and emerging therapy options expected to change the treatment landscape.

October 23, 2021

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.

October 10, 2021

Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.

October 09, 2021

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.